You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 159 No. 15, August 9, 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editor's Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (41)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Pulmonary Edema Associated With Troglitazone Therapy

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We report 2 cases of pulmonary edema associated with the use of troglitazone (Rezulin; Parke-Davis, Morris Plains, NJ).

Report of a Case.

Case 1.

A 65-year-old woman with type 2 diabetes began troglitazone therapy. Her hemoglobin A1c fraction improved from 0.10 to 0.06. After 8 months of therapy, she reported lower-extremity edema, which became severe. The findings of her physical examination were otherwise unremarkable, and there was no proteinuria. Furosemide therapy was initiated, but the edema progressed. After 13 months, she had shortness of breath and orthopnea. Details are noted in Table 1. A chest x-ray film showed pulmonary edema. An electrocardiogram and an adenosine stress test with a tetrofosmin perfusion scan revealed no abnormalities. A gated blood pool sample showed an ejection fraction of 0.62, with a normal left ventricle. After the troglitazone therapy was discontinued, the patient's fluid overload improved, and she lost 7.1 kg after 3 weeks.


 
Table appears in full text version.
Clinical Characteristics of 2 Cases . . . [Full Text of this Article]


Case 2.


Comment.
Irl B. Hirsch, MD; Janet Kelly, PharmD; Stephanie Cooper, MD
Seattle, Wash



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

TZDs: Where Do We Go From Here?
Hirsch
DOC News 2007;4:3-3.
FULL TEXT  

Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone
Khan et al.
Am. J. Physiol. Renal Physiol. 2005;289:F442-F450.
ABSTRACT | FULL TEXT  

Collecting duct-specific deletion of peroxisome proliferator-activated receptor {gamma} blocks thiazolidinedione-induced fluid retention
Zhang et al.
Proc. Natl. Acad. Sci. USA 2005;102:9406-9411.
ABSTRACT | FULL TEXT  

Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis
Graziadei et al.
Lupus 2003;12:409-412.
ABSTRACT  

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure
Tang et al.
J Am Coll Cardiol 2003;41:1394-1398.
ABSTRACT | FULL TEXT  

Reflections
Hirsch
Clin. Diabetes 2002;20:162-164.
FULL TEXT  

Troglitazone-Induced Pulmonary Edema
Inoue et al.
Arch Intern Med 2000;160:871-872.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.